CompletedPhase 4

Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion

Iceland9 participantsStarted 2013-05

Plain-language summary

This exploratory pilot study was an open-label, crossover, single-center and non-randomized clinical trial designed to compare the effect of the standardly employed doses of allopurinol (400 mg/day) and febuxostat (80 mg/day) on the urinary 2,8-dihydroxyadenine (DHA) excretion in patients with adenine phosphoribosyltransferase (APRT) deficiency.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients 18 year and older who are enrolled in the APRT Deficiency Registry of The Rare Kidney Stone Consortium. Exclusion Criteria: * Patients do not want to interrupt drug (allopurinol) treatment for a total of two weeks as requested in protocol. No other exclusion criteria if inclusion criteria are met.

What they're measuring

Urinary 2,8-dihydroxyadenine Excretion

Timeframe: 7, 21 and 42 days

Trial details

NCT IDNCT02752633

SponsorLandspitali University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-05

Results submitted2017-10-12

View on ClinicalTrials.gov More Adenine Phosphoribosyltransferase Deficiency trials